Pentoxifylline

Excreted Unchanged %
None
Half-Life (Normalesrd) Hours
0.8/Unchanged
Plasma Protein Binding %
None
Volume Of Distribution L/Kg
2.4-4.2
Dose For Normal Renal Function
400 mg tid
Adjustment For Renal Failure Method
I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
q8-12h [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
q12-24h [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
q24h [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Baker DE, Campbell RK. Pentoxifylline: a new agent for intermittent claudication. Drug Intell Clin Pharm. 1985; 19: 345-8. [PMID: 3891279] / Beermann B, Ings R, M&#229; nsby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther. 1985; 37: 25-8. [PMID: 3965236] / Paap CM, Simpson KS, Horton MW, Schaefer KL, Lassman HB, Sack MR. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. Ann Pharmacother. 1996; 30: 724-9. [PMID: 8826548] / Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987; 34: 50-97. [PMID: 3308412]